Cargando…
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers
B7-H3 (CD276) has emerged as a target for cancer immunotherapy by virtue of consistent expression in many malignancies, relative absence from healthy tissues, and an emerging role as a driver of tumor immune inhibition. Recent studies have reported B7-H3 to be a suitable target for chimeric antigen...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467911/ https://www.ncbi.nlm.nih.gov/pubmed/36159778 http://dx.doi.org/10.1016/j.omto.2022.08.008 |
_version_ | 1784788296095760384 |
---|---|
author | Birley, Kathleen Leboreiro-Babe, Clara Rota, Enrique Miranda Buschhaus, Magdalena Gavriil, Artemis Vitali, Alice Alonso-Ferrero, Maria Hopwood, Lee Parienti, Lara Ferry, Gabrielle Flutter, Barry Himoudi, Nourredine Chester, Kerry Anderson, John |
author_facet | Birley, Kathleen Leboreiro-Babe, Clara Rota, Enrique Miranda Buschhaus, Magdalena Gavriil, Artemis Vitali, Alice Alonso-Ferrero, Maria Hopwood, Lee Parienti, Lara Ferry, Gabrielle Flutter, Barry Himoudi, Nourredine Chester, Kerry Anderson, John |
author_sort | Birley, Kathleen |
collection | PubMed |
description | B7-H3 (CD276) has emerged as a target for cancer immunotherapy by virtue of consistent expression in many malignancies, relative absence from healthy tissues, and an emerging role as a driver of tumor immune inhibition. Recent studies have reported B7-H3 to be a suitable target for chimeric antigen receptor-modified T cell (CAR-T) therapy using CARs constructed from established anti-B7-H3 antibodies converted into single-chain Fv format (scFv). We constructed and screened binders in an scFv library to generate a new anti-B7-H3 CAR-T with favorable properties. This allowed access to numerous specificities ready formatted for CAR evaluation. Selected anti-human B7-H3 scFvs were readily cloned into CAR-T and evaluated for anti-tumor reactivity in cytotoxicity, cytokine, and proliferation assays. Two binders with divergent complementarity determining regions were found to show optimal antigen-specific cytotoxicity and cytokine secretion. One binder in second-generation CD28-CD3ζ CAR format induced sustained in vitro proliferation on repeat antigen challenge. The lead candidate CAR-T also demonstrated in vivo activity in a resistant neuroblastoma model. An empirical approach to B7-H3 CAR-T discovery through screening of novel scFv sequences in CAR-T format has led to the identification of a new construct with sustained proliferative capacity warranting further evaluation. |
format | Online Article Text |
id | pubmed-9467911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-94679112022-09-22 A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers Birley, Kathleen Leboreiro-Babe, Clara Rota, Enrique Miranda Buschhaus, Magdalena Gavriil, Artemis Vitali, Alice Alonso-Ferrero, Maria Hopwood, Lee Parienti, Lara Ferry, Gabrielle Flutter, Barry Himoudi, Nourredine Chester, Kerry Anderson, John Mol Ther Oncolytics Original Article B7-H3 (CD276) has emerged as a target for cancer immunotherapy by virtue of consistent expression in many malignancies, relative absence from healthy tissues, and an emerging role as a driver of tumor immune inhibition. Recent studies have reported B7-H3 to be a suitable target for chimeric antigen receptor-modified T cell (CAR-T) therapy using CARs constructed from established anti-B7-H3 antibodies converted into single-chain Fv format (scFv). We constructed and screened binders in an scFv library to generate a new anti-B7-H3 CAR-T with favorable properties. This allowed access to numerous specificities ready formatted for CAR evaluation. Selected anti-human B7-H3 scFvs were readily cloned into CAR-T and evaluated for anti-tumor reactivity in cytotoxicity, cytokine, and proliferation assays. Two binders with divergent complementarity determining regions were found to show optimal antigen-specific cytotoxicity and cytokine secretion. One binder in second-generation CD28-CD3ζ CAR format induced sustained in vitro proliferation on repeat antigen challenge. The lead candidate CAR-T also demonstrated in vivo activity in a resistant neuroblastoma model. An empirical approach to B7-H3 CAR-T discovery through screening of novel scFv sequences in CAR-T format has led to the identification of a new construct with sustained proliferative capacity warranting further evaluation. American Society of Gene & Cell Therapy 2022-08-25 /pmc/articles/PMC9467911/ /pubmed/36159778 http://dx.doi.org/10.1016/j.omto.2022.08.008 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Birley, Kathleen Leboreiro-Babe, Clara Rota, Enrique Miranda Buschhaus, Magdalena Gavriil, Artemis Vitali, Alice Alonso-Ferrero, Maria Hopwood, Lee Parienti, Lara Ferry, Gabrielle Flutter, Barry Himoudi, Nourredine Chester, Kerry Anderson, John A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
title | A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
title_full | A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
title_fullStr | A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
title_full_unstemmed | A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
title_short | A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
title_sort | novel anti-b7-h3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467911/ https://www.ncbi.nlm.nih.gov/pubmed/36159778 http://dx.doi.org/10.1016/j.omto.2022.08.008 |
work_keys_str_mv | AT birleykathleen anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT leboreirobabeclara anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT rotaenriquemiranda anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT buschhausmagdalena anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT gavriilartemis anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT vitalialice anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT alonsoferreromaria anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT hopwoodlee anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT parientilara anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT ferrygabrielle anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT flutterbarry anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT himoudinourredine anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT chesterkerry anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT andersonjohn anovelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT birleykathleen novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT leboreirobabeclara novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT rotaenriquemiranda novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT buschhausmagdalena novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT gavriilartemis novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT vitalialice novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT alonsoferreromaria novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT hopwoodlee novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT parientilara novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT ferrygabrielle novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT flutterbarry novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT himoudinourredine novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT chesterkerry novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers AT andersonjohn novelantib7h3chimericantigenreceptorfromasinglechainantibodylibraryforimmunotherapyofsolidcancers |